GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to pre...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 4.1% | ||
| P/E Ratio | 23.6x | ||
| Revenue | 31.376 B | ||
| Net Income to Company | 2.951 B |
| GSK | Peers | Sector | |
|---|---|---|---|
Market Cap | 60.682 B | 47.463 B | 49.604 M |
Price % of 52 Week High | 81.4% | 84.7% | 62.0% |
Dividend Yield | 4.1% | 2.6% | 0.0% |
Shareholder Yield | 5.7% | 2.4% | -0.7% |
1 Year Price Total Return | -9.3% | 0.0% | -12.0% |
Beta (5 Year) | 0.29 | 0.36 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 29,324 | 30,328 | 31,376 | 8,052 | 8,117 |
| Operating Income | 7,322 | 8,403 | 6,184 | 1,701 | 997 |
| Net Profit | 14,956 | 4,928 | 2,575 | 350 | 414 |
| Diluted EPS | 1.09 | 1.20 | 0.62 | 0.086 | 0.10 |
| EBITDA | 9,293 | 10,304 | 8,313 | 1,931 | 1,529 |
| Balance Sheet | |||||
| Cash & ST Invest. | 8,725 | 5,688 | 4,326 | 5,688 | 4,326 |
| Current Assets | 20,769 | 18,644 | 16,997 | 18,644 | 16,997 |
| Total Assets | 60,146 | 59,005 | 59,463 | 59,005 | 59,463 |
| Current Liabilities | 22,810 | 21,068 | 21,697 | 21,068 | 21,697 |
| Total Liabilities | 50,050 | 46,210 | 46,377 | 46,210 | 46,377 |
| Total Equity | 10,096 | 12,795 | 13,086 | 12,795 | 13,086 |
| Total Debt | 20,987 | 18,018 | 16,986 | 18,018 | 16,986 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 7,403 | 6,768 | 6,554 | 3,196 | 2,329 |
| Cash From Investing | (8,772) | (1,595) | (1,229) | 268 | (1,119) |
| Cash From Financing | 823 | (5,641) | (4,726) | (3,592) | (842) |
| Free Cash Flow | 6,260 | 5,454 | 5,155 | 2,710 | 1,785 |